Mark David Brazeal

Chief Legal Officer Brazeal sells 8,152 shares ($3.2M) in 26 separate transactions over two days at AVGO; retains 269,989 shares post-sale.

Mark David Brazeal, Chief Legal & Corporate Affairs Officer, executed 26 separate sales totaling 8,152 shares for $3,175,919.06 across June 16–17, 2026, reducing his holdings by 2.9% to 269,989 shares. The multi-tranche structure over two consecutive days, with prices ranging from $377.10 to $400.29 and a blended average of $389.59, represents a significant liquidation event, though he retains substantial ownership. At his prior five sales at AVGO (all on 2026-03-17), none were well-timed at the 90-day mark—each subsequent 90-day period showed positive returns (+21.3% to +23.9%), meaning the stock rose after each sale. The current sale occurs against a backdrop where Broadcom's stock has risen 32.5% over 90 days and stands at $411.35, above the transaction prices, suggesting the company maintains strong momentum. With a P/E of 66.78, revenue growth of +23.9%, and $9.3B in net income on $22.2B quarterly revenue, the stock reflects elevated valuation but robust fundamentals. The absence of scheduled-trade flagging means this filing represents discretionary selling activity.

Chief Legal Officer Brazeal sold 83,682 shares (23.1% of holdings) for $27.1M across 19 transactions at AVGO on Mar 16-17

Brazeal Mark David, Chief Legal & Corporate Affairs Officer, executed 19 separate sales totaling 83,682 shares for $27,061,693.75 on March 16-17, reducing his AVGO holdings from 361,823 shares to 278,141 shares—a 23.1% reduction of pre-transaction holdings. The sales were executed across a narrow price band ($317.97–$328.17) with a blended average of $323.39, while the stock currently trades at $315.93 (2.3% below transaction prices). Notably, his 5 prior trades at AVGO have shown consistent timing success: 2 of 2 prior sells were well-timed at the 90-day mark (returns of -5.7% and -2.4%), and his most recent sales on 2026-01-06 already show 30-day declines of -10.7% and -10.5%, continuing a pattern of sales executed ahead of downward price movement. This large, multi-day sale by a C-suite officer warrants attention as a potential signal of outlook or portfolio rebalancing at a senior level.

Chief Legal & Corp Affairs Officer sells 30,000 AVGO shares for $10.4M; stock down 18.2% in 30 days

Brazeal Mark David, Chief Legal & Corporate Affairs Officer, executed two separate sales on 2026-01-06 totaling 30,000 shares for $10,413,692.52 at a blended average price of $347.12, reducing his holdings by 12.5% from 240,573 to 210,573 shares. The transaction occurred as AVGO has declined 18.2% over the prior 30 days and is trading 19.5% below its 52-week high of $412.97, though the stock remains up 2.4% over the 90-day period. The insider's cross-ticker track record shows 20 prior sells; his prior five AVGO trades (all sells in December 2025) remain unmeasurable in terms of 30- and 90-day outcomes. The sale is substantial in dollar terms ($10.4M) and represents a meaningful reduction in a significant holding, occurring during a period of notable price weakness relative to recent highs.

Chief Legal Officer Mark David Brazeal sold 25,921 AVGO shares at $352.07 for $9.1M, reducing holdings by 9.7% to 240,573 shares

Mark David Brazeal, Chief Legal & Corporate Affairs Officer, executed a sale of 25,921 shares at $352.07 on 2025-12-26, representing 9.7% of his pre-transaction holdings and reducing his position from 266,494 to 240,573 shares. The transaction occurred after the stock had already declined 15.3% from its 52-week high of $412.97 and 13.2% over the preceding 30 days, and comes within nine days of four prior sales by the same executive on 2025-12-17. While Broadcom remains well-capitalized with $16.0B in latest quarterly revenue, 23.9% annual growth, and a $1,658.7B market cap, the clustering of sales in the same window warrants attention to whether this reflects a structured disposition plan. Brazeal's cross-ticker track record shows 20 prior sells, though timing outcomes for those cannot yet support a conclusion about this position's strategic intent.

Chief Legal Officer Mark David Brazeal sold 38,281 shares of AVGO for $12,542,614.94 in 23 transactions on 2025-12-17.

Brazeal executed 23 separate sales totaling 38,281 shares for $12,542,614.94 on 2025-12-17, reducing his holdings by 12.6% from 304,775 to 266,494 shares. The transactions were executed at prices ranging from $322.29 to $343.78, with a blended average price of $327.65, while the current price stands at $340.36. Notably, Brazeal sold 5 times at AVGO on 2025-12-16 (the day immediately prior), and those outcomes are not yet measurable at the 30-day and 90-day marks. His cross-ticker track record across 20 prior sells shows an average 90-day return of -2.4% with a 90-day well-timed rate of 100.00%, indicating historical pattern of selling before subsequent declines; however, the specific timing signal of this large block sale cannot yet be assessed given the price has risen 3.7% from his blended average execution price to the current $340.36 level.

CLO Mark Brazeal sold 24,527 shares of AVGO for $8.4M on 2025-12-16 at blended avg $340.91/share; retains 304,775 shares.

Chief Legal & Corporate Affairs Officer Mark Brazeal conducted 11 separate sales totaling 24,527 shares (24.5K shares) for $8,361,499.50 ($8.4M) on 2025-12-16, reducing his holding by 7.4%. The multiple tranches executed across a narrow price range ($337.21–$347.14) with a blended average price of $340.91 were completed on a single trading day. Current price of $329.88 sits 20.1% below the 52-week high of $412.97, and the stock has declined 3.1% over 30 days and 4.4% over 90 days. Brazeal retains a substantial post-transaction position of 304,775 shares (304.8K shares), indicating continued material ownership in the $1,564.1B market-cap company. The company reports strong fundamentals: revenue of $15,952,000,000.00 ($16.0B) in the latest quarter, net income of $4,140,000,000.00 ($4.1B), and annual revenue growth of 23.9%.

CLO Mark Brazeal sold 27,204 shares of AVGO for $9,592,387.01 across 24 transactions on 2025-09-16 to 2025-09-17.

Mark Brazeal, Chief Legal & Corporate Affairs Officer, executed 24 separate sales totaling 27,204 shares for $9,592,387.01 at an average blended price of $352.61, reducing his holdings by 7.6% from 356,506 to 329,302 shares. The multi-day, multi-tranche execution across a narrow price range ($343.13–$365.15) suggests a systematic liquidation rather than a single opportunistic trade. Against current price of $345.35, the insider sold at a blended average $352.61, which is 2.1% above current levels and 6.6% below the 52-week high of $369.57. His prior five trades at AVGO show mixed timing outcomes: three resulted in positive 30-day and 90-day returns (June 2025 and April 2025 sales saw stock appreciation), while his cross-ticker track record across 14 prior sells shows an average 90-day return of -32.0% with a 58.33% well-timed rate, suggesting moderate predictive accuracy historically but no strong pattern of selling into near-term declines. Broadcom's recent fundamentals show strong growth (44.0% annual revenue growth) but an elevated P/E of 271.93, which may constrain further upside valuation expansion.

Brazeal (Chief Legal & Corp Affairs Officer) sold 50,000 AVGO shares at $262.10 on 2025-06-24; stock at $270.17 now.

Brazeal sold 50,000 shares (50.0K shares) for $13,105,050.00 ($13.1M), reducing holdings from 415,956 to 365,956 shares. The sale occurred at $262.10, and the stock has since risen to $270.17, putting the trade underwater by approximately 3%. At the same-ticker level, Brazeal's prior four measurable AVGO sales show mixed timing: one well-timed sell (2025-03-24, 90d return -9.1%), two poorly-timed sells (2025-04-11, 90d unavailable but 30d return +15.7%; 2024-10-11, 90d return +26.4%), and one near-flat sell (2024-12-24, 90d return -19.9%). His cross-ticker track record across 13 prior sells shows a 63.64% well-timed rate at the 90-day mark with an average 90-day return of -39.8%, but that aggregate record does not predict outcomes at Broadcom specifically. The stock is trading at its 52-week high of $270.17, having rallied +59.8% over 90 days, though fundamentals remain stretched with a P/E of 212.73 and revenue growth of +44.0% year-over-year.

Brazeal (Chief Legal & Corp Affairs Ofc) sold 50,000 AVGO shares at $253.28 on 2025-06-23; stock now at $264.65. Post-transaction holdings: 415,956 shares (10.7% reduction).

Mark David Brazeal sold 50,000 shares (50.0K shares) for $12,664,250.00 ($12.7M) at $253.28, reducing his holdings from 465,956 shares to 415,956 shares. The sale occurred 28 days before the stock reached its 52-week high of $264.65, and the stock has risen 15.7% in the 30 days since the transaction. At the same ticker, his cross-ticker track record shows a 90-day well-timed rate of 63.64%, but at AVGO specifically, only 1 of 3 prior sells with measurable 90-day outcomes were well-timed, and his last prior AVGO sale on 2025-04-11 saw the stock rise 15.7% in the subsequent 30 days. The pattern suggests a tendency to exit ahead of near-term rallies at this stock, though the executive retains a substantial position of 415,956 shares in a firm with $15.0B quarterly revenue and 44.0% annual growth.

AVGO Chief Legal Officer sells 25,000 shares ($4.5M) at $180.00; stock down 28.4% from 52-week high and -8.5% in 30 days.

Mark David Brazeal, Chief Legal & Corp Affairs Officer, sold 25,000 shares of Broadcom at $180.00 on 2025-04-11, reducing his holdings by 5.1% to 465,956 shares. The sale occurs against a backdrop of significant recent price weakness: AVGO has fallen 28.4% from its 52-week high of $250.00 and declined 8.5% over the past 30 days and 21.5% over 90 days. Brazeal's cross-ticker track record shows a 70.00% well-timed rate on prior sells with an average 90-day return of -46.6%, though at this specific ticker (AVGO), his prior four measurable sales showed only 1 of 4 with negative 90-day returns, indicating less consistent timing here. The company maintains strong fundamentals with $14.9B in latest quarterly revenue and 44.0% annual revenue growth, though the elevated P/E of 140.91 reflects market expectations already priced into valuation.